Loading…
NVO
Novo Nordisk A S
NYSE· Healthcare· Drug Manufacturers - General· CUSIP 670100205
$39.43+0.95%Price as of Oct 23, 00:41 UTC · updated once a day, after the close
At a glance
Novo Nordisk A S (NVO) is listed on NYSE and classified in Drug Manufacturers - General, part of the Healthcare sector. It is headquartered in Bagsvaerd, Denmark and has 66,700 employees. The company is worth $174.01B and trades at 9.6x its earnings of the last twelve months; the median for its sector is 24.3x. Revenue was DKK 309.06B in fiscal 2025, up 6.4% from the year before. Net income was DKK 102.43B. The share price is 38.5% below its 52-week high of $64.16. It pays a dividend yielding 4.57%, and has raised its annual dividend for 7 years in a row in our records. 9 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Renaissance Technologies, at $145.37M. In that quarter, 3 of them opened or added to the position and 4 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $174.01B
- P/E
- 9.6x
- Forward P/E
- 11.6x
- P/B
- 5.3x
- Dividend yield
- 4.57%
- Payout
- 44.01%
- EPS
- $4.09
- ROE
- 59.81%
- Profit margin
- 35.35%
- Revenue growth
- +2.10%
- Beta
- 0.38
- 52-week high
- $64.16
- 52-week low
- $35.12
History
Year by year, from the annual reports; dividends from the payments themselves.
Revenue, debt and profit are in DKK, the currency the company reports in — not converted to dollars. Dividends are in dollars.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
- Renaissance TechnologiesReducedRenaissance Technologies · Q2 2026$145.37M3.03M shares · 0.2% of portfolio
- Tom GaynerHeldMarkel Group · Q2 2026$137.58M2.87M shares · 1.0% of portfolio
- Israel EnglanderAddedMillennium Management · Q2 2026$97.6M2.04M shares · 0.1% of portfolio
- Lee AinslieReducedMaverick Capital · Q2 2026$79.29M1.65M shares · 0.7% of portfolio
Ken GriffinReducedCitadel Advisors · Q2 2026$65.5M1.37M shares · 0.0% of portfolio- Cliff AsnessAddedAQR Capital Management · Q2 2026$15.54M324.15K shares · 0.0% of portfolio
- Steve CohenNew positionPoint72 Asset Management · Q2 2026$1.4M29.2K shares · 0.0% of portfolio
- Two SigmaReducedTwo Sigma Investments · Q2 2026$757.45K15.8K shares · 0.0% of portfolio
- Baillie GiffordHeldBaillie Gifford & Co · Q2 2026$3.93K82 shares · 0.0% of portfolio
Price over time
▼ -27.3% over 5Y.
today you would have $790.75▼ -20.9%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 4 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Year-end price | $50.88 | $86.02 | $103.45 | $67.67 | |
| EPS | DKK 23.03 | DKK 22.63 | DKK 18.62 | DKK 12.22 | |
| Dividend yield | 1.44% | 3.31% | 1.68% | 1.00% | 1.20% |
| Profit margin | 33.96% | 33.14% | 34.78% | 36.03% | 31.38% |
| ROE | 68.44% | 52.79% | 70.38% | 78.53% | 66.51% |
This company reports in DKK, and the stock trades in dollars. P/E, P/S, P/B and payout would divide dollars by DKK, so they are not shown; EPS is in DKK. Margin, ROE and dividend yield do not depend on the currency.
Median of the years shown; P/E years above 200x are left out.
Fair price, seven ways
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Earnings
$26.20
Square root of 22.5 × earnings × book value. Blind to intangibles, so it undervalues software and brands.
Earnings
$18.67
Earnings growing 0.0% a year plus a 4.6% dividend yield. Growth capped at 25%.
Earnings
$99.33
Median P/E of 24.3 among peers in the sector.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Operating
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Dividends
$118.37
Dividend growing 5.5% a year against a 7.0% required return, from the stock’s beta.
How the average is calculated
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
Earnings $48.07 (avg. of 3)+Dividends $118.37÷ 2 =$83.22
$83.22
4 methods answered, across 2 families.
$62.41
Room for errors in the reported numbers.
$39.43
+111.1% from the average.
Models, not forecasts, and not investment advice. How each formula works →
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| PFEPfizer Inc | $30.42 | 40.0x | 2.0x | 5.65% | 5.01% | $173.38B |
| ABTAbbott Laboratories | $102.51 | 37.4x | 3.4x | 2.46% | — | $177.38B |
| DHRDanaher Corp | $229.75 | 38.7x | 3.0x | 0.70% | 8.19% | $161.51B |
| ISRGIntuitive Surgical Inc | $443.85 | 53.7x | 9.6x | 0.00% | 17.93% | $156.8B |
| GILDGilead Sciences Inc | $157.19 | — | 16.5x | 2.09% | -20.68% | $194.91B |
| VRTXVertex Pharmaceuticals Inc | $535.17 | 31.0x | 6.7x | 0.00% | 23.54% | $135.64B |
About the company
- 66,700
- Bagsvaerd, Denmark